Merck's COVID-19 pill showed it prevented hospitalization or death in unvaccinated adults by 50 percent.
's vaccine cost the government about $40, Moderna's cost about $30 for full vaccination, and Johnson & Johnson's one-dose vaccination was only about $10 per dose, according to the Congressional Research Service.
Merck's oral antiviral pill is less expensive than monoclonal antibody treatments but more expensive than getting vaccinated against COVID-19. Above, employees walk past a Merck sign in front of the company's building on October 2, 2013, in Summit, New Jersey.More than 180 million Americans are fully vaccinated against COVID-19 but despite about 65 percent of the country's population being inoculated, hospitals continue to be overwhelmed.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Covid-19: NHS Covid passes, and lockdown lifted in SydneyFive things you need to know about the coronavirus pandemic this Monday morning.
Lire la suite »
Merck seeks FDA emergency use authorization for antiviral Covid-19 treatment molnupiravirMerck said it is seeking FDA emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.
Lire la suite »
Merck asks the FDA to authorize use of its promising COVID-19 pillDrugmaker Merck has asked U.S. regulators to authorize its promising pill protecting against COVID-19, setting the stage for a decision within weeks.
Lire la suite »
Merck Seeks FDA Authorization for Antiviral COVID-19 PillDrugmaker Merck announced Monday that it submitted an application to the FDA for emergency use authorization of molnupiravir, an experimental antiviral COVID-19 treatment.
Lire la suite »
Where America's cases, hospitalizations, deaths stand 19 months into the COVID-19 pandemicAlthough hospitalizations nationwide have been trending downward since September, more than 40,000 people remain hospitalized with COVID-19.
Lire la suite »